Automotive & Mobility Global On demand · 24-48h

Global Extracellular Vesicle (EV) Isolation Kits Market Strategic Research Report

Global Extracellular Vesicle (EV) Isolation Kits Market Stra…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Extracellular Vesicle (EV) Isolation Kits Market
$5092025
15.4%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Plasma / Serum, Cell culture media, Urine, Others

By Application: Research, Clinical, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Thermo Fisher Scientific, Qiagen, System Biosciences (Sbi), Bio-Techne, Miltenyi Biotec, Izon Science, Norgen Biotek, Lonza Group, Fujifilm Wako Pure Chemical, Abcam, Tiangen Biotech, Beijing Transgen Biotech, Bioground Biotechnology, Sansure Biotech, Daan Gene, Jiangsu Cowin Biotech, Geneaid Biotech, Magen Biotechnology, Beyotime Biotechnology, Servicebio Technology

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 132 pages
Market size 2025
$509
Million USD
Forecast CAGR
15.4%
2025-2032
Forecast 2032
$1387.3
Projected
Области
5
Asia Pacific · Latin America · MEA · Europe · North America

Обзор

Scope of the Report

The global Extracellular Vesicle (EV) Isolation Kits market size is predicted to grow from US$ 509 million in 2025 to US$ 1,378 million in 2032; it is expected to grow at a CAGR of 15.4% from 2026 to 2032.

Extracellular Vesicle (EV) Isolation Kits are laboratory reagent systems designed to extract and purify extracellular vesicles—such as exosomes, microvesicles, and apoptotic bodies—from biological fluids (e.g., plasma, serum, urine, or cell culture media). These kits typically use methods such as precipitation, size exclusion, immunoaffinity capture, or membrane filtration to enrich EVs while removing proteins, lipoproteins, and other contaminants for downstream applications like proteomics, RNA analysis, biomarker discovery, and drug delivery research.In 2025, global Extracellular Vesicle (EV) Isolation Kit production reached approximately 1.37 M units, with an average global market price of around US$ 380 per unit. Annual production capacity is 1.58 M units. Gross Profit Margin: 58%.The EV isolation kit industry chain includes three parts: upstream suppliers, midstream manufacturers, and downstream users. Upstream provides key materials such as antibodies, membranes, and polymers. Midstream companies like Thermo Fisher, Qiagen, and Izon Science produce and commercialize EV isolation kits. Downstream users include research institutes, biotech firms, and clinical labs focusing on liquid biopsy and biomarker discovery.The market is consumable-driven, with recurring kit purchases supporting stable revenue. Research applications dominate today, while clinical adoption is still emerging as standards improve.EV isolation kits are an early-stage but fast-growing market bridging research tools and clinical diagnostics. The field is still fragmented, but is gradually moving toward standardization, especially with SEC and microfluidic technologies.In the long term, companies that offer simple, high-purity, and scalable solutions will likely lead the market as EV-based diagnostics become more widely adopted.

Global key Extracellular Vesicle (EV) Isolation Kits players cover Thermo Fisher Scientific, Qiagen, System Biosciences (Sbi), Bio-Techne, Miltenyi Biotec, etc.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Extracellular Vesicle (EV) Isolation Kits market?

What factors are driving Extracellular Vesicle (EV) Isolation Kits market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Extracellular Vesicle (EV) Isolation Kits market opportunities vary by end market size?

How does Extracellular Vesicle (EV) Isolation Kits break out by Separation Principle, by Application?

This report presents a comprehensive overview of the global Extracellular Vesicle (EV) Isolation Kits market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Sample Type

  • Plasma / Serum
  • Cell culture media
  • Urine
  • Others

Segment by Separation Principle

  • Precipitation
  • Size Exclusion Chromatography, SEC
  • Ultracentrifugation
  • Immunoaffinity
  • Microfluidics
  • Filtration

Segment by Throughput

  • Low-throughput
  • Medium-throughput
  • High-throughput / Automated

Segment by Application

  • Research
  • Clinical
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Extracellular Vesicle (EV) Isolation Kits market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Research, Clinical, Others evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Extracellular Vesicle (EV) Isolation Kits Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 15.4%
Regional growth momentum
Market share by segment
Key metrics
Base value
$509
2025
Forecast
$1387.3
2032
CAGR
15.4%
2025–2032
Области
5
global
Key companies
Thermo Fisher ScientificQiagenSystem Biosciences (Sbi)Bio-TechneMiltenyi BiotecIzon ScienceNorgen BiotekLonza Group
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Plasma / SerumCell culture mediaUrineOthers
By Application
ResearchClinicalOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Plasma / Serum
  • 3.1.3 Cell culture media
  • 3.1.4 Urine
  • 3.1.5 Others
  • 3.1.6 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Research
  • 4.1.3 Clinical
  • 4.1.4 Others
  • 4.1.5 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Thermo Fisher Scientific
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Qiagen
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 System Biosciences (Sbi)
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Bio-Techne
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Miltenyi Biotec
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Izon Science
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Norgen Biotek
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Lonza Group
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Fujifilm Wako Pure Chemical
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Abcam
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Tiangen Biotech
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Beijing Transgen Biotech
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Bioground Biotechnology
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Sansure Biotech
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Daan Gene
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 Jiangsu Cowin Biotech
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 Geneaid Biotech
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
  • 8.18 Magen Biotechnology
  • 8.18.1 Company Overview
  • 8.18.2 Key Products & Segments
  • 8.18.3 Financial Performance (2023–2025)
  • 8.18.4 Business Strategy
  • 8.18.5 SWOT Analysis
  • 8.18.6 Strategic Implications (2026–2032)
  • 8.19 Beyotime Biotechnology
  • 8.19.1 Company Overview
  • 8.19.2 Key Products & Segments
  • 8.19.3 Financial Performance (2023–2025)
  • 8.19.4 Business Strategy
  • 8.19.5 SWOT Analysis
  • 8.19.6 Strategic Implications (2026–2032)
  • 8.20 Servicebio Technology
  • 8.20.1 Company Overview
  • 8.20.2 Key Products & Segments
  • 8.20.3 Financial Performance (2023–2025)
  • 8.20.4 Business Strategy
  • 8.20.5 SWOT Analysis
  • 8.20.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

How big is the global Extracellular Vesicle (EV) Isolation Kits market?
The global Extracellular Vesicle (EV) Isolation Kits market is estimated at US$ 509 million in 2025 (base year) and is projected to reach US$ 1.38 billion by 2032.
How fast is the Extracellular Vesicle (EV) Isolation Kits market expected to grow?
The market is expected to grow at a CAGR of 15.4% from 2026 to 2032, expanding from US$ 509 million in 2025 to US$ 1.38 billion in 2032, roughly 2.7 times its base-year value.
What does the Extracellular Vesicle (EV) Isolation Kits market cover?
Extracellular Vesicle (EV) Isolation Kits are laboratory reagent systems designed to extract and purify extracellular vesicles—such as exosomes, microvesicles, and apoptotic bodies—from biological fluids (e.g., plasma, serum, urine, or cell culture media). Annual production capacity is 1.58 M units.
How is the Extracellular Vesicle (EV) Isolation Kits market segmented by sample type?
By sample type, the market is segmented into Plasma / Serum, Cell culture media, Urine and Others.
What are the key applications of Extracellular Vesicle (EV) Isolation Kits?
Key applications covered include Research, Clinical and Others.
Which companies are profiled in the Extracellular Vesicle (EV) Isolation Kits market report?
Key players profiled include Thermo Fisher Scientific, Qiagen, System Biosciences (Sbi), Bio-Techne, Miltenyi Biotec, Izon Science, Norgen Biotek and Lonza Group, among 20 companies covered in total.
What geographies does the Extracellular Vesicle (EV) Isolation Kits market analysis include?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What are the key demand drivers for Extracellular Vesicle (EV) Isolation Kits?
What factors are driving Extracellular Vesicle (EV) Isolation Kits market growth, globally and by region?
Who should buy the Extracellular Vesicle (EV) Isolation Kits market report?
The report is intended for manufacturers and solution providers, distributors and end users in Research, Clinical and Others, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Extracellular Vesicle (EV) Isolation Kits market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from 3 500,00 $
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.